MCID: CLR017
MIFTS: 44

Clear Cell Sarcoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Clear Cell Sarcoma

MalaCards integrated aliases for Clear Cell Sarcoma:

Name: Clear Cell Sarcoma 12 15 17
Sarcoma, Clear Cell 44 70
Adult Soft Part Clear Cell Sarcoma 12
Malignant Melanoma of Soft Tissues 12
Melanoma, Malignant, of Soft Parts 12
Clear Cell Sarcoma of Soft Parts 12
Malignant Melanoma of Soft Parts 12
Sarcoma Clear Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4233
MeSH 44 D018227
NCIt 50 C27370 C3745
SNOMED-CT 67 12622007
UMLS 70 C0206651 C1332198

Summaries for Clear Cell Sarcoma

Disease Ontology : 12 A sarcoma that is characterized by solid nests and fascicles of tumor cells with clear cytoplasm and prominent nucleoli. It presents as a slow growing mass that especially affects tendons and aponeuroses and it is deeply situated.

MalaCards based summary : Clear Cell Sarcoma, also known as sarcoma, clear cell, is related to melanoma of soft tissue and kidney clear cell sarcoma. An important gene associated with Clear Cell Sarcoma is ATF1 (Activating Transcription Factor 1), and among its related pathways/superpathways are ErbB1 downstream signaling and Transcriptional misregulation in cancer. The drugs Doxorubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include lymph node, tongue and small intestine, and related phenotypes are cellular and embryo

Wikipedia : 73 Clear cell sarcoma is a rare form of cancer called a sarcoma. It is known to occur mainly in the soft... more...

Related Diseases for Clear Cell Sarcoma

Diseases in the Small Cell Sarcoma family:

Clear Cell Sarcoma

Diseases related to Clear Cell Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 354)
# Related Disease Score Top Affiliating Genes
1 melanoma of soft tissue 32.8 EWSR1 CREB1 ATF1
2 kidney clear cell sarcoma 32.6 YWHAE NUTM2E NUTM2B EWSR1 CCNB3 BCOR
3 spindle cell sarcoma 32.1 S100B KIT EWSR1 CCNB3
4 rare tumor 31.5 KIT EWSR1
5 sarcoma 31.2 WT1 TFE3 S100B KIT FUS EWSR1
6 kidney sarcoma 30.7 YWHAE WT1 NUTM2E NUTM2B CCNB3
7 paraganglioma 30.5 SYP S100B KIT ENO2
8 nephroma 30.5 WT1 TFE3 KIT IGF2
9 sarcomatosis 30.5 WT1 EWSR1 ATF1
10 rhabdoid cancer 30.5 WT1 SYP IGF2 EWSR1
11 alveolar soft part sarcoma 30.5 TFE3 SYP ENO2
12 myxoid liposarcoma 30.4 FUS EWSR1 ATF1
13 epithelioid cell melanoma 30.4 MLANA MITF
14 skin melanoma 30.4 SOX10 S100B MLANA MITF KIT
15 neurilemmoma 30.4 SOX10 S100B MITF KIT ENO2
16 myxoid chondrosarcoma 30.3 SYP S100B EWSR1
17 epithelioid malignant peripheral nerve sheath tumor 30.3 SOX10 S100B MLANA
18 neuroblastoma 30.3 SYP KIT IGF2 EWSR1 ENO2 CREB1
19 amelanotic melanoma 30.3 S100B MLANA KIT
20 small cell carcinoma 30.3 SYP KIT ENO2
21 dermatofibrosarcoma protuberans 30.2 S100B KIT ENO2
22 small intestinal sarcoma 30.2 WT1 KIT EWSR1
23 connective tissue benign neoplasm 30.1 MLANA KIT EWSR1 ENO2
24 malignant spindle cell melanoma 30.1 SOX10 MLANA MITF KIT
25 tuberous sclerosis 30.1 SYP S100B MLANA ENO2
26 kidney rhabdoid cancer 30.1 YWHAE SYP NUTM2B EWSR1 ENO2 CCNB3
27 mesenchymal cell neoplasm 30.0 TFE3 MLANA KIT EWSR1 CCNB3
28 microphthalmia 30.0 TFE3 SOX10 S100B MLANA MITF KIT
29 extraosseous chondrosarcoma 29.9 SYP FUS EWSR1 ENO2
30 leiomyosarcoma 29.9 WT1 S100B MLANA KIT IGF2 ENO2
31 congenital mesoblastic nephroma 29.9 YWHAE WT1 NUTM2B KIT IGF2 CCNB3
32 malignant peripheral nerve sheath tumor 29.8 WT1 SOX10 S100B MLANA MITF KIT
33 perivascular epithelioid cell tumor 29.8 TFE3 SYP MLANA MITF KIT
34 sarcoma, synovial 29.8 WT1 S100B KIT IGF2 FUS EWSR1
35 gastrointestinal stromal tumor 29.7 WT1 SYP S100B KIT IGF2 ENO2
36 endometrial stromal sarcoma 29.6 YWHAE S100B NUTM2B KIT EWSR1 CCNB3
37 ewing sarcoma 29.5 WT1 SYP S100B KIT IGF2 FUS
38 fibrous histiocytoma 29.3 S100B MITF KIT FUS EWSR1 ENO2
39 rhabdomyosarcoma 29.2 WT1 SYP S100B KIT IGF2 FUS
40 chondrosarcoma, extraskeletal myxoid 28.8 WT1 SYP SOX10 FUS EWSR1 ENO2
41 wilms tumor 1 11.2
42 melanoma 10.9
43 soft tissue sarcoma 10.8
44 posttransplant acute limbic encephalitis 10.5
45 intracranial cysts 10.4 S100B ENO2
46 bednar tumor 10.4 S100B ENO2
47 penis sarcoma 10.4 MLANA ENO2
48 ewing sarcoma of bone 10.4 EWSR1 ENO2
49 head injury 10.4 S100B ENO2
50 primary hepatic neuroendocrine carcinoma 10.4 SYP S100B

Graphical network of the top 20 diseases related to Clear Cell Sarcoma:



Diseases related to Clear Cell Sarcoma

Symptoms & Phenotypes for Clear Cell Sarcoma

MGI Mouse Phenotypes related to Clear Cell Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 ATF1 BCOR CCNB3 CREB1 ENO2 ERBB3
2 embryo MP:0005380 9.91 ATF1 BCOR CREB1 ERBB3 IGF2 KIT
3 integument MP:0010771 9.81 ERBB3 IGF2 KIT MITF MLANA S100B
4 normal MP:0002873 9.65 ATF1 CREB1 ERBB3 KIT MITF S100B
5 pigmentation MP:0001186 9.17 ERBB3 KIT MITF MLANA SOX10 TFE3

Drugs & Therapeutics for Clear Cell Sarcoma

Drugs for Clear Cell Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
3
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
4
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
5
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
6 Antibiotics, Antitubercular Phase 2, Phase 3
7 Alkylating Agents Phase 2, Phase 3
8
Liposomal doxorubicin Phase 2, Phase 3 31703
9 Anti-Bacterial Agents Phase 2, Phase 3
10
Isophosphamide mustard Phase 2, Phase 3 100427
11
Melphalan Approved Phase 2 148-82-3 4053 460612
12
Etoposide Approved Phase 2 33419-42-0 36462
13
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
14
Dactinomycin Approved, Investigational Phase 2 50-76-0 2019 457193
15
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
16
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
17
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198
18
Vemurafenib Approved Phase 2 918504-65-1 42611257 23252090
19
Ipilimumab Approved Phase 2 477202-00-9
20
nivolumab Approved Phase 2 946414-94-4
21
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
22
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
23
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
24
Pyrazole Experimental Phase 2 288-13-1
25
Enoxolone Investigational Phase 1, Phase 2 471-53-4 18526330
26 Tubulin Modulators Phase 2
27 Immunosuppressive Agents Phase 2
28 Etoposide phosphate Phase 2
29 Antimitotic Agents Phase 2
30 topoisomerase I inhibitors Phase 2
31 Vasodilator Agents Phase 2
32 Angiotensinogen Phase 2
33 Angiotensin I (1-7) Phase 2
34 Antihypertensive Agents Phase 2
35 Immunologic Factors Phase 2
36 Protein Kinase Inhibitors Phase 2
37 Antibodies Phase 2
38 Immunoglobulins Phase 2
39 Antibodies, Monoclonal Phase 2
40 Antimalarials Phase 1, Phase 2
41 Antirheumatic Agents Phase 1, Phase 2
42 Antiparasitic Agents Phase 1, Phase 2
43 Anti-Infective Agents Phase 1, Phase 2
44 Antiprotozoal Agents Phase 1, Phase 2
45
Heparin Approved, Investigational Phase 1 9005-49-6 772 9812414
46
Dalteparin Approved Phase 1 9005-49-6
47
Sunitinib Approved, Investigational Phase 1 557795-19-4, 341031-54-7 5329102
48
Tinzaparin Approved Phase 1 9041-08-1, 9005-49-6 25244225
49
Sargramostim Approved, Investigational Phase 1 123774-72-1, 83869-56-1
50
Topotecan Approved, Investigational Phase 1 123948-87-8, 119413-54-6 60700

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
2 Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK) Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
3 Treatment of High Risk Renal Tumors: A Groupwide Phase II Study Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
4 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
5 A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors Completed NCT00557609 Phase 2 ARQ 197
6 A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
7 Phase 2 Study With COmbination of Vemurafenib With Cobimetinib in B-RAF V600E/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab therapY Recruiting NCT02968303 Phase 2 Vemurafenib and Cobimetinib
8 A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion Recruiting NCT03132155 Phase 2 AMG 337
9 A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma Recruiting NCT04458922 Phase 2 Atezolizumab
10 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Active, not recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
11 Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Active, not recruiting NCT03989596 Phase 2
12 Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE") Active, not recruiting NCT01524926 Phase 2 Crizotinib (PF-02341066)
13 Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma Not yet recruiting NCT04274023 Phase 2 TSR-042
14 A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue Not yet recruiting NCT04593758 Phase 1, Phase 2 CPI-613 + Hydroxychloroquine
15 Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma Completed NCT01061411 Phase 1 Dalteparin;Sunitinib Malate
16 A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients Completed NCT00258687 Phase 1
17 A Phase 1 Study Using Simvastatin in Combination With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Completed NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
18 Sirolimus in Combination With Metronomic Therapy in Children With Recurrent and Refractory Solid Tumors: A Phase I Study Completed NCT01331135 Phase 1 sirolimus
19 Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT03618381 Phase 1
20 Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT04483778 Phase 1
21 Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Renal Tumor Project: Application of Array-Based Methods and Next Generation Sequencing to Identify Candidate Molecular Targets for High-Risk Wilms Tumors Completed NCT01118078
22 Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group Recruiting NCT03967834
23 Renal Tumors Classification, Biology, and Banking Study Recruiting NCT00898365
24 Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers Active, not recruiting NCT02162732

Search NIH Clinical Center for Clear Cell Sarcoma

Cochrane evidence based reviews: sarcoma, clear cell

Genetic Tests for Clear Cell Sarcoma

Anatomical Context for Clear Cell Sarcoma

MalaCards organs/tissues related to Clear Cell Sarcoma:

40
Lymph Node, Tongue, Small Intestine, Skin, Myeloid, Kidney, Colon

Publications for Clear Cell Sarcoma

Articles related to Clear Cell Sarcoma:

(show top 50) (show all 1030)
# Title Authors PMID Year
1
The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells. 61 54
20362353 2010
2
Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. 54 61
20087159 2010
3
Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). 61 54
19561568 2009
4
Clear cell sarcoma of the mediastinum. 61 54
19433300 2009
5
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. 54 61
18627530 2008
6
Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity. 54 61
17075294 2006
7
MITF: master regulator of melanocyte development and melanoma oncogene. 61 54
16899407 2006
8
EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation. 61 54
17000668 2006
9
Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. 54 61
16867224 2006
10
Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. 54 61
16766266 2006
11
Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. 61 54
16258500 2005
12
Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses). 61 54
15588860 2005
13
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. 61 54
15150091 2004
14
The melanocyte inducing factor MITF is stably expressed in cell lines from human clear cell sarcoma. 54 61
12966428 2003
15
Case report: case of clear cell sarcoma surviving with the primary lesion for 20 years after resection of a metastatic lymph node. 54 61
14666625 2003
16
Karyotypic divergence and convergence in two synchronous lung metastases of a clear cell sarcoma of tendons and aponeuroses with t(12;22)(q13;q12) and type 1 EWS/ATF1. 54 61
12935923 2003
17
Cytogenetic comparison between clear cell sarcoma and a case of acral clear cell melanoma. 61 54
16285301 2003
18
Minimal structural elements of an inhibitory anti-ATF1/CREB single-chain antibody fragment (scFv41.4). 54 61
12831531 2003
19
Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. 54 61
11865845 2002
20
Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics. 54 61
11145252 2001
21
Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: further evidence for melanocytic differentiation. 54 61
11211309 2001
22
Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11. 61 54
11063792 2000
23
Tumor cell viability in clear cell sarcoma requires DNA binding activity of the EWS/ATF1 fusion protein. 61 54
10574952 1999
24
New type of chimeric fusion product between the EWS and ATFI genes in clear cell sarcoma (malignant melanoma of soft parts). 61 54
9824209 1998
25
Insulin-like growth factor 2 gene imprinting in clear cell sarcoma of the kidney. 61 54
9385942 1997
26
The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator. 54 61
8552387 1996
27
The emerging molecular genetics of sarcoma translocations. 61 54
7493135 1995
28
Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. 61 54
8187063 1994
29
Clear cell sarcoma of the kidney expresses insulinlike growth factor-II but not WT1 transcripts. 54 61
8424465 1993
30
Clear cell sarcoma of the kidney in Austrian children: Long-term survival after relapse. 61
33438324 2021
31
Successful transcatheter arterial embolization to control intratumoral hemorrhage in clear cell sarcoma of the kidney. 61
33692305 2021
32
Pathologic nodal staging for clinically node negative soft tissue sarcoma of the extremities. 61
33751586 2021
33
Ultrasound-based screening and characterization of an atypical clear-cell sarcoma of the hand. 61
33781734 2021
34
Diagnostic accuracy and cytomorphological spectrum of Wilms tumour in fine needle aspiration biopsy cytology samples supplemented with cell blocks. 61
33745231 2021
35
Retrospective analysis of outcomes in patients with clear cell sarcoma of the kidney: A tertiary single-institution experience. 61
33272561 2021
36
INSM1 Expression in Angiosarcoma. 61
33210141 2021
37
Fine Needle Aspiration Cytology of Malignant Digestive System Gastrointestinal Neuroectodermal Tumor in a Lymph Node Metastasis from a Previously Diagnosed Liver Primary: A Case Report and Review of Literature. 61
32975903 2021
38
Hypoglycemia Due to Acquired Carnitine Deficiency in a Pediatric Patient Receiving Chemotherapy. 61
33661167 2021
39
[Multicenter clinical study on the diagnosis and treatment of childhood renal tumor]. 61
33657693 2021
40
Malignant gastrointestinal neuroectodermal tumor with BRAF mutation and a history of malignant melanoma: A case report. 61
33335731 2021
41
[Uterine malignant perivascular epithelioid cell tumor (PEComa): Two case reports]. 61
32646778 2021
42
A Population-based Analysis of Lymph Node Metastasis in Extremity Soft Tissue Sarcoma: An Update. 61
33561723 2021
43
Clear cell sarcoma of soft tissue with eccrine differentiation: A case report and review of the literature. 61
33599302 2021
44
Malignant gastrointestinal neuroectodermal tumor (clear cell sarcoma-like tumor of the gastrointestinal tract) of the small intestine in a 12-year-old boy. 61
33745250 2021
45
Primary clear cell sarcoma of the femur: a unique case with RT-PCR and direct sequencing confirmation of EWSR1/ATF1 fusion gene. 61
33478436 2021
46
Primary Clear Cell Sarcoma of the Ileum: A Case Report With Next-Generation Sequencing Analysis. 61
33412984 2021
47
An obstructive role of NK cells on metastatic growth of clear-cell sarcoma cells in a xenoplant murine model. 61
33262889 2021
48
Clear cell tumor with melanocytic differentiation and MITF-CREM translocation: a novel entity similar to clear cell sarcoma. 61
33462743 2021
49
Specific and Sensitive Diagnosis of BCOR-ITD in Various Cancers by Digital PCR. 61
33718245 2021
50
[Detection of BCOR and YWHAE-NUTM2B/E in clear cell sarcoma of the kidney in children]. 61
33287519 2020

Variations for Clear Cell Sarcoma

Expression for Clear Cell Sarcoma

Search GEO for disease gene expression data for Clear Cell Sarcoma.

Pathways for Clear Cell Sarcoma

GO Terms for Clear Cell Sarcoma

Cellular components related to Clear Cell Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATF4-CREB1 transcription factor complex GO:1990589 8.62 CREB1 ATF1

Biological processes related to Clear Cell Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.97 WT1 TFE3 SOX10 MITF KIT FUS
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.87 WT1 TFE3 SOX10 MITF IGF2 CREB1
3 positive regulation of gene expression GO:0010628 9.8 WT1 SOX10 MITF KIT ERBB3
4 positive regulation of transcription, DNA-templated GO:0045893 9.73 WT1 TFE3 SOX10 MITF FUS CREB1
5 regulation of osteoclast differentiation GO:0045670 9.43 TFE3 MITF
6 regulation of transcription, DNA-templated GO:0006355 9.28 WT1 TFE3 SOX10 MITF IGF2 FUS
7 positive regulation of cardiac muscle tissue development GO:0055025 9.16 ERBB3 CREB1
8 melanocyte differentiation GO:0030318 9.13 SOX10 MITF KIT

Molecular functions related to Clear Cell Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.81 YWHAE SYP SOX10 S100B FUS EWSR1
2 DNA-binding transcription factor activity GO:0003700 9.73 WT1 TFE3 SOX10 MITF CREB1 ATF1
3 transcription regulatory region sequence-specific DNA binding GO:0000976 9.35 WT1 TFE3 SOX10 CREB1 BCOR
4 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.1 WT1 TFE3 SOX10 MITF CREB1 ATF1

Sources for Clear Cell Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....